Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263


Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV.

Nature. 2012 May 16;485(7399):512-6. doi: 10.1038/nature11087.


Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease.

Zlokovic BV.

JAMA Neurol. 2013 Apr;70(4):440-4. doi: 10.1001/jamaneurol.2013.2152. Review.


Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.

Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV.

J Cereb Blood Flow Metab. 2016 Jan;36(1):216-27.


Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice.

Alata W, Ye Y, St-Amour I, Vandal M, Calon F.

J Cereb Blood Flow Metab. 2015 Jan;35(1):86-94. doi: 10.1038/jcbfm.2014.172. Epub 2014 Oct 22.


Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner.

Johnson LA, Olsen RH, Merkens LS, DeBarber A, Steiner RD, Sullivan PM, Maeda N, Raber J.

Neurobiol Dis. 2014 Apr;64:150-62. doi: 10.1016/j.nbd.2013.12.016. Epub 2014 Jan 9.


Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model.

Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M.

J Biol Chem. 2011 May 20;286(20):17536-42. doi: 10.1074/jbc.M111.225532. Epub 2011 Apr 6.


Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo.

Dieckmann M, Beil FT, Mueller B, Bartelt A, Marshall RP, Koehne T, Amling M, Ruether W, Cooper JA, Humphries SE, Herz J, Niemeier A.

J Bone Miner Res. 2013 Feb;28(2):236-45. doi: 10.1002/jbmr.1757.


Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2.

Klein RC, Mace BE, Moore SD, Sullivan PM.

Neuroscience. 2010 Dec 29;171(4):1265-72. doi: 10.1016/j.neuroscience.2010.10.027. Epub 2010 Oct 15.


Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury.

Ezra Y, Oron L, Moskovich L, Roses AD, Beni SM, Shohami E, Michaelson DM.

Neuroscience. 2003;121(2):315-25.


Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice.

Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y.

J Neurosci. 2012 Apr 4;32(14):4803-11. doi: 10.1523/JNEUROSCI.0033-12.2012.


apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV.

J Clin Invest. 2008 Dec;118(12):4002-13. doi: 10.1172/JCI36663. Epub 2008 Nov 13.


Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice.

Ophir G, Meilin S, Efrati M, Chapman J, Karussis D, Roses A, Michaelson DM.

Neurobiol Dis. 2003 Feb;12(1):56-64.


APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.

Kunzler J, Youmans KL, Yu C, Ladu MJ, Tai LM.

Neurosci Lett. 2014 Feb 7;560:131-6. doi: 10.1016/j.neulet.2013.12.032. Epub 2013 Dec 22.


Apolipoprotein E expression and purification.

Newhouse Y, Weisgraber KH.

Methods Mol Biol. 2011;670:127-40. doi: 10.1007/978-1-60761-744-0_10.


Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.

Baum L, Chen L, Ng HK, Pang CP.

Microsc Res Tech. 2000 Aug 15;50(4):278-81. Review.


APOE genotype alters glial activation and loss of synaptic markers in mice.

Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, LaDu MJ.

Glia. 2012 Apr;60(4):559-69. doi: 10.1002/glia.22289. Epub 2012 Jan 6.


Supplemental Content

Support Center